Ambit Biosciences is combining the power of our KINOMEscan™ kinase profiling technology with an innovative licensing strategy and a history of kinase expertise to discover, optimize and advance a sustainable pipeline of small molecule kinase inhibitors for the treatment of cancer.
| Website | http://ambitbio.com |
| Revenue | $25.7 million |
| Employees | 209 (62 on RocketReach) |
| Founded | 2000 |
| Phone | +1 858-334-2100 |
| Industry | Biotechnology Research, Business Services General, Business Services |
| Keywords | Kinase Inhibitors, Lead Optimization, Drug Licensing, Target Discovery, Drug Discovery, Medicinal Chemistry, Drug Development, Small Molecule Drugs, Therapeutic Development, Pharmaceutical Research, Molecular Biology, Biotechnology, Pharmaceutical, Biopharma, Precision Medicine, Life Sciences, Oncology, Clinical Trials |
| Competitors | Amgen, Incyte, bluebird bio, CureVac, Allogene Therapeutics, REGENXBIO Inc., Sangamo Therapeutics, Inc., Abeona Therapeutics, Axovant Sciences Ltd, Conatus Pharmaceuticals Inc. +43 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Ambit employee's phone or email?
The Ambit annual revenue was $25.7 million in 2026.
Cynthia Kwasny is the Owner of Ambit.
62 people are employed at Ambit.
The NAICS codes for Ambit are [325, 32, 3254, 32541].
The SIC codes for Ambit are [28, 283].